Page 1 | Search Results | Hematology, ASH Education Program

1-16 of 16

Sort by

Sort Order Select

Journal Articles

What to do with minimal residual disease testing in myeloma

Elisabet E. Manasanch

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 137–141.

https://doi.org/10.1182/hematology.2019000080

Published: 2019

Journal Articles

Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?

Surbhi Sidana, Elisabet Manasanch

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 142–147.

https://doi.org/10.1182/hematology.2019000075

Published: 2019

Journal Articles

Minimal residual disease and stem cell transplantation outcomes

Jacqueline Cloos, Gert J. Ossenkoppele, Richard Dillon

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 617–625.

https://doi.org/10.1182/hematology.2019000006

Published: 2019

Journal Articles

MRD evaluation of AML in clinical practice: are we there yet?

Sylvie D. Freeman, Christopher S. Hourigan

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 557–569.

https://doi.org/10.1182/hematology.2019000060

Published: 2019

Journal Articles

Is molecular remission the goal of multiple myeloma therapy?

Faith E. Davies

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 205–211.

https://doi.org/10.1182/asheducation-2017.1.205

Published: 2017

Journal Articles

Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation

Monika Brüggemann, Michaela Kotrova

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 13–21.

https://doi.org/10.1182/asheducation-2017.1.13

Published: 2017

Journal Articles

MRD in AML: does it already guide therapy decision-making?

Gert Ossenkoppele, Gerrit Jan Schuurhuis

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 356–365.

https://doi.org/10.1182/asheducation-2016.1.356

Published: 2016

Journal Articles

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?

David Grimwade, Sylvie D. Freeman

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 222–233.

https://doi.org/10.1182/asheducation.V2014.1.222.3884425

Published: 2014

Journal Articles

Detection and management of minimal residual disease in acute lymphoblastic leukemia

Martin Schrappe

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 244–249.

https://doi.org/10.1182/asheducation-2014.1.244

Published: 2014

Journal Articles

Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patient

Martin Schrappe

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 137–142.

https://doi.org/10.1182/asheducation.V2012.1.137.3798216

Published: 2012

Journal Articles

Malignant or benign leukocytosis

Tracy I. George

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 475–484.

https://doi.org/10.1182/asheducation.V2012.1.475.3798515

Published: 2012

Journal Articles

A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia?

Paolo Ghia

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 97–104.

https://doi.org/10.1182/asheducation.V2012.1.97.3798195

Published: 2012

Journal Articles

Minimal Residual Disease in Acute Lymphoblastic Leukemia

Dario Campana

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 7–12.

https://doi.org/10.1182/asheducation-2010.1.7

Published: 2010

Journal Articles

Evolving paradigms in the therapy of Philadelphia chromosome–negative acute lymphoblastic leukemia in adults

Mark R. Litzow

Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 362–370.

https://doi.org/10.1182/asheducation-2009.1.362

Published: 2009

Journal Articles

Stem Cell Mobilization

Michele H. Cottler-Fox, Tsvee Lapidot, Isabelle Petit, Orit Kollet, John F. DiPersio, Dan Link, Steven Devine

Hematology Am Soc Hematol Educ Program (2003) 2003 (1): 419–437.

https://doi.org/10.1182/asheducation-2003.1.419

Published: 2003

Journal Articles

Acute Lymphoblastic Leukemia

Dieter Hoelzer, Nicola Gökbuget, Oliver Ottmann, Ching-Hon Pui, Mary V. Relling, Frederick R. Appelbaum, Jacques J.M. van Dongen, Tomasz Szczepański

Hematology Am Soc Hematol Educ Program (2002) 2002 (1): 162–192.

https://doi.org/10.1182/asheducation-2002.1.162

Published: 2002

NARROW

What to do with minimal residual disease testing in myeloma

Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?

Minimal residual disease and stem cell transplantation outcomes

MRD evaluation of AML in clinical practice: are we there yet?

Is molecular remission the goal of multiple myeloma therapy?

Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation

MRD in AML: does it already guide therapy decision-making?

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?

Detection and management of minimal residual disease in acute lymphoblastic leukemia

Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patient

Malignant or benign leukocytosis

A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia?

Minimal Residual Disease in Acute Lymphoblastic Leukemia

Evolving paradigms in the therapy of Philadelphia chromosome–negative acute lymphoblastic leukemia in adults

Stem Cell Mobilization

Acute Lymphoblastic Leukemia

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only